SCHOOL OF PUBLIC HEALTH

Department of Global Health and Population

Estimating the non-health benefits of universal health care (UHC) for people with tuberculosis (TB)

Averi Chakrabarti

Email: achakrabarti@@hsph.harvard.edu

October 3, 2019, TB-MAC meeting, Istanbul

Background

A new approach for the economic evaluation of health policies toward UHC in the post-2015 era

Background contd.

Sustainable Development Goal 1

"End poverty in all its forms everywhere"



Sustainable Development Goal 3

"Achieve universal health coverage, including financial risk protection for all"



Extended cost-effectiveness analysis (ECEA)

Incorporates equity and non-health benefits in the economic evaluation of policies



ECEA overview

- Builds on standard cost-effectiveness analysis (CEA)
- Identifies impacts on health and other dimensions
 - Investigates financial risk protection (FRP):
 Quantifies household medical impoverishment averted by policy
- Highlights distributional consequences across different strata of the population (e.g. socioeconomic status, geographical setting, gender)

Examine specific policy

(e.g. public finance for TB treatment)

Health gains

(e.g. TB-related deaths averted)

Household expenditure averted

(e.g. private TB treatment expenses averted)

FRP benefits

(e.g. household impoverishment averted)

Poorest

Poor


Middle

Rich

Richest




What you are getting for a given budget, e.g. \$1,000,0000



Results used to calculate \$ per unit of health benefit (e.g. death averted) and \$ per FRP provided (e.g. poverty case averted)

SCHOOL OF PUBLIC HEALTH

Disaggregating results by wealth quintiles



Results used to calculate \$ per unit of health benefit (e.g. death averted) and \$ per FRP provided (e.g. poverty case averted)



A data intensive process

- Program costs
- Health: Disease incidence, existing treatment coverage rates, case fatality rate
- FRP: Income, Out-of-pocket (OOP) expenditures
 - Direct costs (treatment and transportation costs)
 - Indirect costs (forgone income)
- Equity: Inputs disaggregated by sub-populations

ECEA of TB control interventions

Case 1: ECEA of universal public finance of TB treatment in India

| Outcome | Total | Income Quintile I | Income Quintile II | Income Quintile III | Income Quintile IV | Income Quintile V |
|----------------------------------|----------|-------------------------|--------------------------|---------------------------|--------------------------|-------------------------|
| TB deaths averted | 80 | 40 | 25 | 12 | 3 | 0 |
| Private expenditures crowded out | \$30,000 | 6,000 | 6,000 | 7,000 | 7,000 | 4,000 |
| Financial risk protection | \$10,000 | 5,000 | 2,000 | 1,000 | 1,000 | <1,000 |


Summary benefits over 1 year for 1M Indians

Adapted from:

Verguet, Laxminarayan, et al. Health Economics 2015



Case 2: ECEA of the End TB Strategy in India and South Africa, 2016-2035



Verguet, Riumallo-Herl, Gomez, et al. Lancet Global Health 2017



Case 3: ECEA of the End TB Strategy in Ethiopia, 2016-2035

- Study in progress
- Evaluates scaling up of:
 - DOTs implementation
 - Drug resistance treatment
 - Active TB case finding
- Outcomes
 - TB cases/deaths
 - Catastrophic healthcare spending
 - Inequality

Authors:
Lelisa Fekadu,
Nabila Shaikh,
Rein Houben,
Tigist Menkir,
Mieraf Tolla,
Abdulrahman Jbaily,
Stéphane Verguet



Next steps

Pursue ECEA case studies

- Different TB interventions: cash transfers, public finance, control/elimination
- Different delivery platforms: facility vs. outreach
- Subnational analyses: province, district

More data needed on:

- OOP spending and household expenditures
- Distribution of burden of disease by key population subgroups
- Transmission within and across subgroups

Emails:

Averi Chakrabarti: achakrabarti@hsph.harvard.edu

Stephane Verguet: verguet@hsph.harvard.edu

ECEA publications:

https://www.hsph.harvard.edu/stephane-verguet/